





**Figure 1.** Selected NOESY correlations of **2**.

-11b, and -14 were suggested by the NOESY correlations between H-11b and H-14 and between H-1 and H-15 (Figure 1). This assumption was supported by comparative studies of its  $^{13}\text{C}$  NMR spectral data with those of antirhine (**5**).<sup>12</sup> Biogenetic considerations that the non-dopamine portion of **2** originated from secologanin, and thereby the chirality of C-2 should be *S*, allowed assignment of the absolute stereochemistry of **2**. Thus, alangine was determined to be structure **2**.

The occurrence of **1** and **2** is of great interest from the viewpoint of biosynthesis of *Alangium* alkaloids.<sup>13</sup> Alkaloid **1** could be derived from tubulosine (**3**) or isotubulosine (**4**). Two plausible mechanisms could be proposed for the formation of **3** and **4**. Two epimeric alkaloids might be independently biosynthesized through condensation of a protoemetine type alkaloid with tryptamine (or serotonin) in a manner similar to the biosynthesis of deacetylpeicoside and deacetylisopeicoside.<sup>14</sup> Another possibility is an oxidation–hydrogenation mechanism as observed in the conversion of (*S*)-reticuline to (*R*)-reticuline via the 1,2-dehydroreticulinium ion.<sup>15</sup> In the latter case **1** should be an intermediate between **3** and **4**. Alkaloid **1** could also be oxidized to 1',2',3',4'-tetrahydrotubulosine in *Pogonopus speciosus*.<sup>16</sup> On the other hand, alkaloid **2** is the first compound with a new basic skeleton, which could be formed from **6**, a common intermediate to 10-*O*-demethylprotoemetinol (**7**).<sup>17</sup>

## Experimental Section

**General Experimental Procedures.** UV spectra were recorded on a Shimadzu UV-240 spectrophotometer and IR spectra on a Shimadzu FTIR-8200 spectrophotometer. Optical rotations were measured on a Jasco DIP-370 digital polarimeter and CD spectra on a Shimadzu-AV19 62 A DS circular dichroism spectrometer.  $^1\text{H}$  (500 MHz) and  $^{13}\text{C}$  (125 MHz) NMR spectra were recorded on a Varian VXR-500 spectrometer with TMS as an internal standard. MS and HRMS were obtained with a Hitachi M-4100 mass spectrometer. MPLC was carried out with Wakogel FC-40. TLC was performed on precoated Kieselgel 60F<sub>254</sub> plates (Merck).

**Plant Material.** The dried fruits of *Alangium lamarckii*, collected in India, were purchased from Mikuni, Osaka, Japan. A voucher specimen (KPFY-921) is deposited in our laboratory.

**Extraction and Isolation.** The dried fruits (4.5 kg) of *A. lamarckii* were crushed and extracted with hot MeOH, and the extracts were fractionated as described previously.<sup>2</sup> A part (426 g) of the residue (556 g) from the H<sub>2</sub>O layers was redissolved in H<sub>2</sub>O, basified with Na<sub>2</sub>CO<sub>3</sub>, and extracted with Et<sub>2</sub>O and C<sub>2</sub>H<sub>4</sub>Cl<sub>2</sub> successively. The residue (8.8 g) from the Et<sub>2</sub>O layer was subjected to MPLC, and elution with CHCl<sub>3</sub>/MeOH mixtures of the indicated MeOH content gave 5 fractions: 1 (2%, 171 mg), 2 (2–5%, 2.49 g), 3 (8%, 1.75 g), 4 (10–15%, 2.44 g), 5 (20–25%, 192 mg). Fraction 1 was purified by preparative TLC (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH, 85:15:1.5) to afford protoemetine (15.2 mg) and deoxytubulosine (11.6 mg). Fraction 2 was purified by MPLC (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH, 98:2:0.2

to 90:9:1) and preparative TLC (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH, 90:9:1), affording protoemetine (4.8 mg), deoxytubulosine (83.9 mg), protoemetinol (8.8 mg), neocephaline (97.0 mg), 2'-*N*-(1''-deoxy-1''-β-D-fructopyranosyl)cephaline (25.5 mg), cephaline (1.39 g), and isocephaline (109 mg). In the same way, the following fractions were purified by a combination of MPLC with CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH (98:2:0.2 to 90:9:1) and preparative TLC with CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH (90:9:1) or C<sub>6</sub>H<sub>6</sub>/EtOAc/Et<sub>2</sub>NH (2:7:1). Fraction 3 yielded deoxytubulosine (28.0 mg), neocephaline (28.6 mg), cephaline (1.15 g), and isocephaline (154 mg); fraction 4, **3** (224 mg), **4** (23.6 mg), 2'-*N*-(1''-deoxy-1''-β-D-fructopyranosyl)cephaline (4.7 mg), cephaline (345 mg), isocephaline (899 mg), psychotrine (37.9 mg), and 10-*O*-demethylcephaline (24.5 mg); fraction 5, **3** (57.0 mg), **1** (10.9 mg), **4** (16.2 mg), cephaline (10.2 mg), and isocephaline (119 mg). The C<sub>2</sub>H<sub>4</sub>Cl<sub>2</sub> layer (6.4 g) was also subjected to MPLC, and elution with CHCl<sub>3</sub>/MeOH mixtures of the indicated that the MeOH content gave 7 fractions: 1 (2%, 69.3 mg), 2 (2%, 245 mg), 3 (5%, 1.90 g), 4 (5–8%, 2.01 g), 5 (8%, 587 mg), 6 (8–20%, 826 mg), 7 (20%, 335 mg). Each fraction was purified in a manner similar to that for the Et<sub>2</sub>O layer to yield protoemetine (41.4 mg), cephaline (1650 mg), isocephaline (985 mg), deoxytubulosine (26.1 mg), neocephaline (16.1 mg), 2'-*N*-(1''-deoxy-1''-β-D-fructopyranosyl)cephaline (74.9 mg), psychotrine (596 mg), alangiside (96.0 mg), **3** (6.2 mg), **4** (3.4 mg), salsoline (2.8 mg), and **2** (3.0 mg). The known alkaloids were identified by comparisons ( $[\alpha]_D$ , UV, IR, NMR, and MS) with pure standards.

**1',2'-Dehydrotubulosine (1):** amorphous powder;  $[\alpha]_D^{18}$  +2.1° (*c* 0.42, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 230sh (4.20), 291 (3.69), 328 (4.04), 370sh (3.67) nm; CD (MeOH)  $\lambda_{\text{max}}$  ( $\Delta \epsilon$ ) 211 (+8.7), 223 (–2.1) nm; IR (KBr)  $\nu_{\text{max}}$  3432, 2833, 2748, 1612, 1514 cm<sup>-1</sup>;  $^1\text{H}$  NMR (CD<sub>3</sub>OD)  $\delta$  1.00 (3H, t, *J* = 7.5 Hz, H<sub>3</sub>-13), 1.17 (1H, dt, *J* = 13.5, 11.5 Hz, H-1), 1.24–1.32 (3H, m, H-12, H<sub>2</sub>-α), 1.55 (1H, m, H-3), 1.81 (1H, m, H-2), 1.85 (1H, d, *J* = 13.5, 7.5, 3.0 Hz, H-12), 2.03 (1H, ddd, *J* = 13.5, 4.0, 3.0 Hz, H-1), 2.10 (1H, t, *J* = 11.5 Hz, H-4), 2.50 (1H, m, H-6), 2.65 (1H, dt, *J* = 14.0, 4.0 Hz, H-7), 2.96 (2H, m, H<sub>2</sub>-4), 2.99–3.18 (3H, m, H-6, H-7, H-11b), 3.11 (1H, dd, *J* = 11.5, 4.0 Hz, H-4), 3.27 (3H, s, 10-OMe), 3.72 (3H, s, 9-OMe), 3.78 (1H, m, H-3'), 3.92 (1H, dt, *J* = 15.0, 7.0 Hz, H-3'), 6.19 (1H, s, H-11), 6.61 (1H, s, H-8), 6.90 (1H, dd, *J* = 8.5, 2.5 Hz, H-7'), 6.92 (1H, dd, *J* = 2.5, 0.5 Hz, H-5'), 7.28 (1H, dd, *J* = 8.5, 0.5 Hz, H-8');  $^{13}\text{C}$  NMR (CD<sub>3</sub>OD)  $\delta$  11.5 (C-13), 20.5 (C-4'), 24.5 (C-12), 29.3 (C-7), 30.8 (C-α), 37.2 (C-1), 42.0 (C-2), 43.4 (C-3), 47.3 (C-3'), 53.6 (C-6), 56.1 (10-OMe), 56.4 (9-OMe), 61.8 (C-4), 63.6 (C-11b), 104.0 (C-5'), 109.1 (C-11), 113.1 (C-8), 114.4 (C-8'), 118.7 (C-7'), 119.4 (C-4'a), 127.0 (C-5'a), 127.5 (C-7a), 130.3 (C-11a), 130.6 (C-9'a), 135.5 (C-8'a), 148.6 (C-10), 149.2 (C-9), 153.0 (C-6'), 166.4 (C-1'); NOESY correlations H-11/OMe ( $\delta$  3.27); H-11/H-1 ( $\delta$  2.03); H-8/OMe ( $\delta$  3.78); H-8/H-7 ( $\delta$  2.65); EIMS *m/z* 473 [M]<sup>+</sup>, 272, 270, 244, 201, 200, 192, 176, 146; HR-EIMS *m/z* 473.2648 (calcd for C<sub>29</sub>H<sub>35</sub>N<sub>3</sub>O<sub>3</sub>, 473.2680).

**Alangine (2):** amorphous powder;  $[\alpha]_D^{30}$  –0.95° (*c* 0.21, MeOH);  $[\alpha]_D^{23}$  –2.5° (*c* 0.20, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 225sh (3.74), 285 (3.45) nm; CD (MeOH)  $\lambda_{\text{max}}$  ( $\Delta \epsilon$ ) 206 (–4.8), 219 (+1.4), 235 (+0.7) nm; IR (KBr)  $\nu_{\text{max}}$  3569, 2975, 1613, 1516, 1457 cm<sup>-1</sup>;  $^1\text{H}$  NMR (CDCl<sub>3</sub>)  $\delta$  1.68 (1H, m, H-2), 1.71–1.81 (2H, m, H<sub>2</sub>-3), 2.14 (2H, m, H<sub>2</sub>-1), 2.35 (1H, m, H-14), 2.71 (1H, m, H-7), 2.84 (2H, m, H<sub>2</sub>-4), 3.07 (1H, m, H-6), 3.09 (1H, m, H-7), 3.19 (1H, m, H-6), 3.57 (1H, dd, *J* = 10.5, 7.5 Hz, H-15), 3.79 (1H, dd, *J* = 10.5, 4.5 Hz, H-15), 3.86 (3H, s, OMe), 4.07 (1H, m, H-11b), 5.17 (1H, ddd, *J* = 17.0, 1.5, 0.5 Hz, H-12), 5.23 (1H, dd, *J* = 10.0, 1.5 Hz, H-12), 5.60 (1H, ddd, *J* = 17.0, 10.0, 9.5 Hz, H-13), 6.57 (1H, s, H-8), 6.77 (1H, s, H-11);  $^{13}\text{C}$  NMR (CDCl<sub>3</sub>)  $\delta$  25.0 (C-7), 27.4 (C-3), 31.0 (C-2), 31.5 (C-1), 47.8 (C-4), 49.0 (C-14), 50.7 (C-6), 55.9 (OMe), 56.8 (C-11b), 63.5 (C-15), 111.0 (C-8), 111.2 (C-11), 118.8 (C-12), 124.5 (C-7a), 127.0 (C-11a), 138.1 (C-13), 144.5 (C-10), 145.7 (C-9); NOESY correlations H-1/H-11; H<sub>2</sub>-7/H-8; H<sub>2</sub>-15/H<sub>2</sub>-1; H-11b/H-14; H-14/H-12 ( $\delta$  5.23); OMe/H-8; H-12 ( $\delta$  5.17)/H-14; EIMS *m/z* 303 [M]<sup>+</sup>, 302, 272, 232, 230, 191, 178, 176; HREIMS *m/z* 303.1858 (calcd for C<sub>18</sub>H<sub>25</sub>NO<sub>3</sub>, 303.1836).

**Reduction of 1',2'-Dehydrotubulosine (1).** A methanolic solution (1 mL) of 1',2'-dehydrotubulosine (**1**) (4.9 mg) was

stirred with NaBH<sub>4</sub> (75 mg) for 10 min at room temperature. The mixture was then diluted with H<sub>2</sub>O and extracted with CHCl<sub>3</sub>, and the extract was washed, dried, and concentrated. The residue (5.0 mg) was purified by preparative TLC (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH, 85:15:1.5) to give **3** (1.7 mg) and **4** (1.1 mg). UV, IR, <sup>1</sup>H NMR, EIMS, optical rotation ( $[\alpha]_{D}^{27} -60^{\circ}$  (*c* 0.16, MeOH)), and CD ((MeOH)  $\lambda_{\max}$  ( $\Delta \epsilon$ ) 229 (−9.5), 242 (+1.6) nm) spectra of **3** were identical with those of the authentic tubulosine. UV, IR, <sup>1</sup>H NMR, EIMS, optical rotation ( $[\alpha]_{D}^{27} -74^{\circ}$  (*c* 0.10, MeOH)), and CD ((MeOH)  $\lambda_{\max}$  ( $\Delta \epsilon$ ) 220 (−15.5), 241 (+2.6) nm) spectra of **4** were identical with those of the authentic isotubulosine.

**Acknowledgment.** Our thanks go to Dr. M. Sugiura (Kobe Pharmaceutical University) for the NMR spectra and to Dr. K. Saiki (Kobe Pharmaceutical University) for the MS measurements.

### References and Notes

- (1) Fujii, T.; Ohba, M. In *The Alkaloids. Chemistry and Pharmacology*; Brossi, A., Ed.; Academic Press: New York, 1983; Vol. 22, Chapter 1, pp 1–50.
- (2) Itoh, A.; Tanahashi, T.; Nagakura, N. *J. Nat. Prod.* **1995**, *58*, 1228–1239.
- (3) Itoh, A.; Tanahashi, T.; Nagakura, N. *Phytochemistry* **1996**, *41*, 651–656.
- (4) Itoh, A.; Tanahashi, T.; Nagakura, N. *Phytochemistry* **1997**, *46*, 1225–1229.
- (5) Itoh, A.; Tanahashi, T.; Nagakura, N. *Heterocycles* **1998**, *48*, 499–505.
- (6) Wiegrebe, W.; Kraamer, W. J.; Shamma, M. *J. Nat. Prod.* **1984**, *47*, 397–408.
- (7) Itoh, A.; Ikuta, Y.; Baba, Y.; Tanahashi, T.; Nagakura, N. *Phytochemistry* **1999**, *52*, 1169–1176.
- (8) Achari, B.; Ali, E.; Ghosh Dastidar, P. P.; Sinha, R. R.; Pakrashi, S. C. *Planta Med.* **1980**, Suppl., 5–7.
- (9) Shoeb, A.; Raj, K.; Kapil, R. S.; Popli, S. P. *J. Chem. Soc., Perkin Trans. 1* **1975**, 1245–1248.
- (10) Johns, S. R.; Lamberton, J. A.; Ocolowitz, J. L. *Aust. J. Chem.* **1967**, *20*, 1463–1471.
- (11) Weniger, B.; Anton, R.; Varea, T.; Quirion, J.-C.; Bastida, J.; Garcia, R. *J. Nat. Prod.* **1994**, *57*, 287–290.
- (12) Kan-Fan, C.; Brillanceau, M. H.; Husson, H. P. *J. Nat. Prod.* **1986**, *49*, 1130–1132.
- (13) Bhakuni, D. S.; Jain, S.; Chaturvedi, R. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1949–1952.
- (14) De-Eknankul, W.; Ounaron, A.; Tanahashi, T.; Kutchan, T. M.; Zenk, M. H. *Phytochemistry* **1997**, *45*, 477–484.
- (15) De-Eknankul, W.; Zenk, M. H. *Phytochemistry* **1992**, *31*, 813–821.
- (16) Ito, A.; Lee, Y.-H.; Chai, H.-B.; Gupta, M. P.; Farnsworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Kinghorn, A. D. *J. Nat. Prod.* **1999**, *62*, 1346–1348.
- (17) Ali, E.; Sinha, R. R.; Achari, B.; Pakrashi, S. C. *Heterocycles* **1982**, *19*, 2301–2304.

NP0000163